# IMbassador250 (NCT03016312)

> A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus enzalutamide
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03016312
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Prostatic Neoplasms, Castration-Resistant
- Interventions: Atezolizumab; Enzalutamide
- Enrollment: 759
- Primary outcome: Overall Survival (OS)

## Indexed commentary on IMbassador250 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=imbassador250-nct03016312